Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

ponse was shown to correlate with good clinical outcomes, including improved overall survival.

The improved RNA amplification process is being used in Argos Therapeutics' ADAPT Phase 3 clinical study for AGS-003, the company's most advanced product candidate. To create AGS-003, RNA is isolated from a small tumor sample obtained from standard tumor removal surgery (nephrectomy), and dendritic cells are taken during a single leukapheresis procedure. The tumor RNA is used to "program" the dendritic cells with the entire disease-antigen repertoire to trigger an immune response against the patient's specific cancer. These antigen-loaded dendritic cells are formulated into a ready-to-use, intradermal injection.

For more information about AGS-003 and the ADAPT study, visit www.ADAPTkidneycancer.com.

About the Arcelis™ Technology Platform

Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.

The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.

Arcelis technology also overcomes many of the manufact
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
(Date:9/2/2015)... -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... supplier of injectable drug delivery systems, today announced that ... Company,s Board of Directors has engaged Morgan Stanley  & ... to maximize shareholder value. Potential strategic ... process may include a possible sale of the Company, ...
(Date:9/2/2015)... WORCESTER, Mass. and ... -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB: ... intention to implement a buccal cannabis co-development ... ) has been formalized. Generex ... Co-Development and Technology Licensing Agreement.  Pursuant to ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2Unilife Announces Review of Strategic Alternatives 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... 2012  Bio-Pharmaceutical and medical device leaders are re-evaluating ... increasing regulatory and market pressures in the U.S., ... Best Practices, LLC. To identify which ... growth in the quickly changing healthcare industry, Best ...
... the premier providers of innovative supplies for continuous positive ... its fifth year with a variety of planned new ... high-quality standards and innovation that the home health care ... Circadiance has its sights set on being the ...
Cached Medicine Technology:Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies 2Circadiance to Launch New Respiratory Supply Products 2
(Date:9/2/2015)... ... 2015 , ... The medical waste management market is expected to reach USD ... 5.2%. The global medical waste management market is segmented based on type of waste, ... to register the highest growth rate in the medical waste management market, by service, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces a crowdfunding ... actress as the primary love interest in the film. The campaign is being called ... affects how and what we think,” Michael Elliot, an award-winning screenwriter and CEO of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... food banks in commemorating “Hunger Action Month” during the entire month of September. ... Food Bank will be dedicating its efforts this September to an awareness campaign ...
(Date:9/2/2015)... ... September 02, 2015 , ... Since 2011, DoMyOwnPestControl.com ... Atlanta to help support childhood cancer research. On June 17, 2014, the ... Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com sponsors each year. The very ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
Breaking Medicine News(10 mins):Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 4Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 5Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4
... North America -, PRINCETON, N.J., Dec. 18 ... Barr has been named Covance,s Chief,Operating Officer, effective ... of Early Development North America, will assume operating,responsibility ... to,Joe Herring, Covance,s Chairman and Chief Executive Officer. ...
... slightly more effective than traditional lung scans, , , TUESDAY, ... a life-threatening blood clot in the lungs -- can ... a technique using CT scanning might be slightly more ... Canadian researchers found that computed tomographic pulmonary angiography (CTPA) ...
... team of researchers led by Mayo Clinic have designed a ... to destroy cancer cells that spread from primary tumors to ... addition, their study shows that this technology could be the ... , The study appeared in the Dec. 9 online issue ...
... screenings for those with severe illnesses, they may bring ... a recent study by Yale School of Medicine researchers ... study offers a new approach for assessing who is ... recommendations can be tailored more effectively to individual patients. ...
... NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ), ... and hospitals throughout the United States,today announced that ... Healthcare,Conference, January 10, 2008, at 8:30 a.m. PST ... Paul Berger, Chairman and CEO, Tim Mayleben, President,and ...
... Dec. 18 Psoriasis Cure Now,a nonprofit patient ... an association between severe psoriasis and a significantly,increased ... psoriasis research. The,study, by a team of University ... severe psoriasis have a 50 percent,increased risk of ...
Cached Medicine News:Health News:Wendel Barr Appointed Chief Operating Officer of Covance 2Health News:Wendel Barr Appointed Chief Operating Officer of Covance 3Health News:CT Scans Catch More Clots in Lungs 2Health News:CT Scans Catch More Clots in Lungs 3Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 3Health News:Colon cancer screenings may not pay off and could pose harm to some 2Health News:NightHawk Radiology Holdings, Inc. to Speak at Annual JPMorgan Healthcare Conference on January 10, 2008 2
Histopathology Reference Laboratory provides a full range of histology services, encompassing routine and specialized grossing, processing, embedding, microtomy, routine and special staining and cove...
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
Medicine Products: